Estradiol/mesoprogestin - Schering

Drug Profile

Estradiol/mesoprogestin - Schering

Alternative Names: Mesoprogestin/estradiol - Schering

Latest Information Update: 12 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Class
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Menopausal syndrome

Most Recent Events

  • 12 Jul 2006 No development reported - Phase-II for Menopausal syndrome in Europe (PO)
  • 08 Aug 2001 New profile
  • 08 Aug 2001 Phase-II clinical trials for Menopausal syndrome in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top